<SEC-DOCUMENT>0001193125-20-193772.txt : 20200716
<SEC-HEADER>0001193125-20-193772.hdr.sgml : 20200716
<ACCEPTANCE-DATETIME>20200716093229
ACCESSION NUMBER:		0001193125-20-193772
CONFORMED SUBMISSION TYPE:	SC 14D9/A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200716
DATE AS OF CHANGE:		20200716

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN N.V.
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 14D9/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-54659
		FILM NUMBER:		201030868

	BUSINESS ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912
		BUSINESS PHONE:		31-77-35566-00

	MAIL ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QIAGEN NV
		DATE OF NAME CHANGE:	19960531

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN N.V.
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 14D9/A

	BUSINESS ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912
		BUSINESS PHONE:		31-77-35566-00

	MAIL ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QIAGEN NV
		DATE OF NAME CHANGE:	19960531
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 14D9/A
<SEQUENCE>1
<FILENAME>d96714dsc14d9a.htm
<DESCRIPTION>SC 14D9/A
<TEXT>
<HTML><HEAD>
<TITLE>SC 14D9/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE <FONT
STYLE="white-space:nowrap">14D-9</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(RULE <FONT STYLE="white-space:nowrap">14d-101)</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SOLICITATION/RECOMMENDATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&nbsp;2) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>QIAGEN N.V.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Subject Company) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>QIAGEN N.V.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Persons Filing Statement) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
shares, par value EUR 0.01 per share </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Title of Class&nbsp;of Securities) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N72482123 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(CUSIP Number
of Class&nbsp;of Securities) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Roland Sackers </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chief Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QIAGEN N.V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hulsterweg
82 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5912 PL Venlo </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Tel:&nbsp;011-31-77-355-6600</FONT></FONT></FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address and telephone numbers of person authorized to receive notices and communications </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on behalf of the persons filing statement) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>With
copies to: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Jonathan L. Kravetz, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Matthew J. Gardella, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>John P. Condon, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One Financial Center </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02111 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(617)&nbsp;542-6000</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Check the box if the filing relates solely to preliminary communications made before the commencement of a tender
offer. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;2 to Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> (this
&#147;<I>Amendment No.</I><I></I><I>&nbsp;2</I>&#148;) amends and supplements the Solicitation/Recommendation Statement on <FONT STYLE="white-space:nowrap">Schedule&nbsp;14D-9</FONT> originally filed with the Securities and Exchange Commission (the
&#147;<I>SEC</I>&#148;) on May&nbsp;18, 2020 (the &#147;<I>Initial <FONT STYLE="white-space:nowrap">Schedule&nbsp;14D-9</FONT></I>,&#148; as amended by Amendment No.&nbsp;1 to <FONT STYLE="white-space:nowrap">Schedule&nbsp;14D-9,</FONT> filed with
the SEC on June&nbsp;15, 2020, together with any subsequent amendments and supplements thereto, the &#147;<I><FONT STYLE="white-space:nowrap">Schedule&nbsp;14D-9</FONT></I>&#148;) by QIAGEN N.V., a public limited liability company (<I>naamloze
vennootschap</I>) organized under the laws of The Netherlands registered with the trade register in The Netherlands under file number&nbsp;12036979 (&#147;<I>QIAGEN</I>&#148;) relating to the tender offer by Quebec B.V. (&#147;<I>Bidder</I>&#148;),
a private limited liability company (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) organized under the laws of The Netherlands and a wholly owned subsidiary of Thermo Fisher Scientific Inc., a Delaware corporation (&#147;<I>Thermo
Fisher</I>&#148;), for all issued ordinary shares, par value &#128;0.01 per share (the &#147;<I>QIAGEN Shares</I>&#148;), of QIAGEN (the &#147;<I>Offer</I>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8. Additional Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item
8 of the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> is hereby amended and supplemented by adding the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;On
July&nbsp;16, 2020, Thermo Fisher and QIAGEN entered into an Amendment (the &#147;<I>Amendment</I>&#148;) to the Business Combination Agreement, dated as of March 3, 2020, by and between Thermo Fisher and QIAGEN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amendment provides for, among other things, an increase to the offer price from EUR&nbsp;39.00 per QIAGEN Share to EUR&nbsp;43.00 per
QIAGEN Share, and a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN&#146;s issued and outstanding ordinary share capital at the end of the acceptance period for the Offer (the &#147;<I>Acceptance Period</I>&#148;),
excluding, for the avoidance of doubt, any QIAGEN Shares held by QIAGEN in treasury at the end of the Acceptance Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to and
subject to the terms of the Amendment, QIAGEN has agreed to pay to Thermo Fisher an expense reimbursement payment of $95&nbsp;million in cash under certain circumstances if the minimum acceptance threshold is not satisfied by the end of the
Acceptance Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thermo Fisher will make available an amendment to the Offer Document to effect the amendment of the terms of the Offer
under applicable securities laws. As a result of the amendment to the Offer Document, the Acceptance Period will be extended by two (2) weeks pursuant to the German Securities Acquisition and Takeover Act and will expire on August&nbsp;10, 2020,
24:00&nbsp;hours (Frankfurt am Main local time)&nbsp;/&nbsp;18:00&nbsp;hours (New York City local time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board and
Managing Board of QIAGEN (the &#147;<I>Boards</I>&#148;) unanimously approved the Amendment and unanimously recommend that QIAGEN Shareholders accept the Offer and tender their QIAGEN Shares in the Offer. QIAGEN expects promptly (i)&nbsp;to publish
in Germany a supplement to its Joint Reasoned Position Statement (the &#147;<I>Supplement</I>&#148;) and (ii)&nbsp;to file the Supplement as part of a further amendment to the Schedule <FONT STYLE="white-space:nowrap">14D-9.</FONT> The Supplement
and further amendment to the <FONT STYLE="white-space:nowrap">Schedule&nbsp;14D-9</FONT> will provide detailed information about the factors considered by the Boards in their recommendation with respect to the revised transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, QIAGEN issued an <FONT STYLE="white-space:nowrap">ad-hoc</FONT> announcement and jointly with Thermo Fisher a press
release announcing the execution of the Amendment. A copy of the <FONT STYLE="white-space:nowrap">ad-hoc</FONT> announcement is attached hereto as Exhibit (a)(5)(P) and is incorporated herein by reference. A copy of the press release is attached
hereto as Exhibit (a)(5)(Q) and is incorporated herein by reference.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9. Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibit list in Item 9 of the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> is hereby amended and supplemented by adding Exhibits
(a)(5)(P), (a)(5)(Q) and (e)(27) as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>(a)(5)(P)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ad Hoc Announcement issued by QIAGEN N.V. on July&nbsp;16, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>(a)(5)(Q)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joint Press Release issued by Thermo Fisher Scientific Inc. and QIAGEN N.V., dated July&nbsp;16, 2020 (incorporated by reference to Exhibit&nbsp;99.1 to the Current Report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> filed
by QIAGEN N.V. with the SEC on July&nbsp;16, 2020).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>(e)(27)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment dated as July&nbsp;16, 2020 to the Business Combination Agreement, dated as of March&nbsp;3, 2020, by and between Thermo Fisher Scientific Inc. and QIAGEN N.V. (incorporated by reference to Exhibit&nbsp;2.1 to the <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed by Thermo Fisher Scientific Inc. with the U.S. Securities and Exchange Commission on July&nbsp;16, 2020).*</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or
exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, that QIAGEN may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or
exhibits so furnished. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">QIAGEN N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Roland Sackers</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Roland Sackers</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;16, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(5)(P)
<SEQUENCE>2
<FILENAME>d96714dex99a5p.htm
<DESCRIPTION>EX-99.(A)(5)(P)
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.(A)(5)(P)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit (A)(5)(P) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g96714g29y88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key word(s): Increased Offer for QIAGEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ad hoc Announcement according to Art. 17 Market Abuse Regulation </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Thermo Fisher to increase cash consideration and lower Acceptance Threshold in Offer for all shares of QIAGEN N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Venlo, The Netherlands, July</B><B></B><B>&nbsp;16, 2020 &#150;</B> QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (&#147;QIAGEN&#148; or the
&#147;Company&#148;) announces that Thermo Fisher Scientific Inc. (NYSE: TMO, &#147;Thermo Fisher&#148;) and QIAGEN have entered into an amendment to the Business Combination Agreement in connection with the ongoing public tender offer (the
&#147;Offer&#148;) to all QIAGEN shareholders for the acquisition of all issued ordinary shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the amended agreement,
Quebec B.V., the wholly-owned subsidiary of Thermo Fisher making the public tender Offer, will increase the cash consideration offered per QIAGEN share from EUR 39.00 to EUR&nbsp;43.00. Furthermore, Thermo Fisher and QIAGEN have agreed to lower the
minimum acceptance threshold, which is a condition to the Offer, from 75% to 66.67% and a USD&nbsp;95&nbsp;million expense reimbursement payable by QIAGEN to Thermo Fisher if the minimum acceptance threshold is not met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Managing Board and the Supervisory Board of QIAGEN consider, under the terms of and subject to the conditions of the amended Business Combination
Agreement, the Offer, as amended, and further transactions related to the Offer to be in the best interest of QIAGEN and its stakeholders (including its shareholders) and have <FONT STYLE="white-space:nowrap">re-affirmed</FONT> their unanimous
support and recommendation of the Offer for acceptance to QIAGEN&#146;s shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An amendment to the Offer Document will be published by Quebec B.V.
in accordance with the German Securities Acquisition and Takeover Act and Thermo Fisher and/or Quebec B.V. will file with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) an amendment to the tender offer statement on Schedule TO. As a
result of the amendment to the Offer Document, the acceptance period will be extended by two weeks until August&nbsp;10, 2020, 24:00 hours (midnight) CEST (18:00 hours New York local time). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QIAGEN N.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hulsterweg 82 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5912 PL Venlo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Netherlands </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ISIN: NL0012169213 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt Stock Exchange, Regulated Market
(Prime Standard) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts QIAGEN N.V.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Gilardi, Tel:
+49 2103 29 11711; john.gilardi@qiagen.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g96714g99c92.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section&nbsp;27A of the U.S.
Securities Act of 1933, as amended, and Section&nbsp;21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to the recommended offer by Thermo Fisher Scientific, Inc. and the
expected benefits related to the proposed transaction are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited
to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer
classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected
changes in technologies; fluctuations in demand for QIAGEN&#146;s products (including fluctuations due to general economic conditions, the level and timing of customers&#146; funding, budgets and other factors); our ability to obtain regulatory
approval of our products; difficulties in successfully adapting QIAGEN&#146;s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from
competitors&#146; products; market acceptance of QIAGEN&#146;s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural
disasters, political or public health crises, including the breadth and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure
events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition by Thermo Fisher Scientific Inc., may not materialize as expected; and the other factors discussed under the
heading &#147;Risk Factors&#148; contained in Item 3 of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F.</FONT> For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished
to, the U.S. Securities and Exchange Commission (SEC). </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN
or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. The terms and conditions of the tender offer are published in, and the offer to
purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (<I>Bundesanstalt f&uuml;r Finanzdienstleistungsaufsicht</I>) and related offer
materials prepared by Thermo Fisher and its acquisition subsidiary. The offer document and related offer materials have been published in Germany and filed with the SEC in a tender offer statement on Schedule TO on May&nbsp;18, 2020, as amended from
time to time. QIAGEN has filed a solicitation/recommendation statement on Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> with the SEC with respect to the tender offer on May&nbsp;18, 2020, as amended from time to time; in addition, QIAGEN
has published a document combining the recommendation statement pursuant to Sec. 27 of the German Securities Acquisition and Takeover Act (<I>Wertpapiererwerbs- und &Uuml;bernahmegesetz,</I><I></I><I> &#147;</I>Wp&Uuml;G&#148;) and the position
statement (<I>gemotiveerde standpuntbepaling</I>) pursuant to Section&nbsp;18 and appendix G of the Dutch Decree on Public Takeovers (<I>Besluit Openbare Biedingen)</I>. The offer document for the tender offer (in German and in English) containing
the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at&nbsp;https://corporate.thermofisher.com/en/offer.html. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. With
respect to the acceptance of the tender offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE TENDER OFFER MATERIALS (INCLUDING THE OFFER DOCUMENT, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE
SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE <FONT STYLE="white-space:nowrap">14D-9</FONT> AND QIAGEN&#146;S RECOMMENDATION STATEMENT PURSUANT TO SEC. 27 WP&Uuml;G AND POSITION STATEMENT (<I>GEMOTIVEERDE STANDPUNTBEPALING</I>) PURSUANT TO
SECTION&nbsp;18 AND APPENDIX G OF THE DUTCH DECREE ON PUBLIC TAKEOVERS (<I>BESLUIT OPENBARE BIEDINGEN),</I> AS THEY MAY BE AMENDED FROM TIME TO TIME,<I> </I>CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g96714g99c92.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AND CONDITIONS
OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tender offer materials, including the offer document and the related letter of transmittal and certain other tender offer documents, and the
solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC&#146;s website at www.sec.gov or at QIAGEN&#146;s website at www.qiagen.com or by contacting
QIAGEN&#146;s investor relations department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">240-686-2222</FONT></FONT> or at Thermo Fisher&#146;s website at www.thermofisher.com or by contacting Thermo Fisher&#146;s investor
relations department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">781-622-1111.</FONT></FONT> In addition, Thermo Fisher&#146;s tender offer statement and other documents filed with the SEC are available at
https://ir.thermofisher.com/investors. Furthermore, copies of the offer document are also available free of charge&nbsp;by contacting D.F. King&nbsp;&amp; Co., Inc., Thermo Fisher&#146;s information agent for the tender offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g96714g29y88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96714g29y88.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MH+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 0W49DMV4'%5'1DRV,I;>9WVA&SZD5T2
MFK'.HNY+=6\BREE1F''09J8274IQ8^*VE-N^5P3C -2Y*XU%V*Z6\S.%V,/4
MD5<IJQ*BR6Z@D$K$*6!Z$#-3"2L4TTQT5K(;63(PQQ@&ESI-!RMIE=+>5Y N
MQAZY'2M)35B8Q=S;7A17*=(M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MC4DH,RK;5;VVNEF6XD9MV6!8G?[5LZ4&K,SC4DCTY3E0?:O(/2%H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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56G]Q?RHN',^X>6G]Q?RHN',^Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g96714g99c92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96714g99c92.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 AZ''6@#!
M<-O._P"]GG-=D=M#D>^I/+YGV.'=G;S41MS,IWLA+/?]H&ST.:<[6U"%[Z$+
M9W'=G/?-4B63S"3[+#NSMYJ(VYF7*]E<+/?]H&ST.:*EK:BA>^A7.03G.>]6
MO(DV;/=]E3?UKEG:^ATPV)ZDH* "@ H * "@ H * "@ H * "@ H * "@ H
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M@L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H 1@"I!Z$4 >::K:Z7I^K&T;6[.%B>$D?#*,]
M.*]:G.<X<W*SS*BA"7+S(WM5T6QM_#L#M?10K;@MY[GY7SS_ /JKFIUI.H]-
MSHJ4XJFM=BGX3LM.OKIKF+4K>[\H$;(6SC(QS6F)J3BN5Q:N1AXPD[IW,W4K
M33+'5C9/KEG&Y;A)'^9?8UK"I.<.;E9E.,(RY7)&[K&C6-MH$$K7T4"VX_UT
MC85\US4JTG4>FYT5:<5!.]K%7PG9:=>SO=0ZE;W?E KLA;.,C&3GZU>)G**Y
M7&Q&'C&3NG<R[^UTRRU8V+:Y9(Y; 61_F7V/;-;PJ3E#FY693C",N7F1Z%IE
MG'8:?#;Q-N51][^]GO7EU).<G)GH0BHQLBW4%A0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M#)=WDOL^_M./K36XGL?+5^MTFH7*WN1=>8WFANN[/-?6P:<5R['R=3F4FI;G
M4:]#JZ?#_P .FY$HM TN >V3\F?PSBN2BZ?UB:COH==95%AX7VU_X!!\/4U!
MO%T']G[@P1]Y'3&TXS^.*K&\BHOF)P7-[9<ISEZDR7UPMT&$_F'S _7.>]=4
M+.*Y=CEG=2:>YU/B.'5T\$>'#=B06H$@ .>.1MS^&<5QT'3]O/EW.RNJBH0Y
MMAGPX6_;Q9&;#>"(9/,(Z8V'&?\ @6*>-Y%1M+R)P2FZWN^9R]PDR7$JW 83
M[B'#_>W=\^]=:::5MCD=T]=SZ'\ +>)X*TY;[=YVP[=W4)D[?TQ7S6+Y?;2Y
M3Z;"*2HQYCI:Y3I"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MHY(A]?Q'=?<O\@_X131_^?>3_P ")/\ XJCDB'U_$=U]R_R#_A%-'_Y]Y/\
MP(D_^*HY(A]?Q'=?<O\ (/\ A%-'_P"?>3_P(D_^*HY(A]?Q'=?<O\@_X131
M_P#GWD_\")/_ (JCDB'U_$=U]R_R#_A%-'_Y]Y/_  (D_P#BJ.2(?7\1W7W+
M_(/^$4T?_GWD_P# B3_XJCDB'U_$=U]R_P @_P"$4T?_ )]Y/_ B3_XJCDB'
MU_$=U]R_R#_A%-'_ .?>3_P(D_\ BJ.2(?7\1W7W+_(/^$4T?_GWD_\  B3_
M .*HY(A]?Q'=?<O\@_X131_^?>3_ ,")/_BJ.2(?7\1W7W+_ "#_ (131_\
MGWD_\")/_BJ.2(?7\1W7W+_(/^$4T?\ Y]Y/_ B3_P"*HY(A]?Q'=?<O\@_X
M131_^?>3_P ")/\ XJCDB'U_$=U]R_R#_A%-'_Y]Y/\ P(D_^*HY(A]?Q'=?
M<O\ (/\ A%-'_P"?>3_P(D_^*HY(A]?Q'=?<O\@_X131_P#GWD_\")/_ (JC
MDB'U_$=U]R_R#_A%-'_Y]Y/_  (D_P#BJ.2(?7\1W7W+_(/^$4T?_GWD_P#
MB3_XJCDB'U_$=U]R_P @_P"$4T?_ )]Y/_ B3_XJCDB'U_$=U]R_R#_A%-'_
M .?>3_P(D_\ BJ.2(?7\1W7W+_(/^$4T?_GWD_\  B3_ .*HY(A]?Q'=?<O\
M@_X131_^?>3_ ,")/_BJ.2(?7\1W7W+_ "#_ (131_\ GWD_\")/_BJ.2(?7
M\1W7W+_(/^$4T?\ Y]Y/_ B3_P"*HY(A]?Q'=?<O\@_X131_^?>3_P ")/\
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M/_BJ.2(?7\1W7W+_ "#_ (131_\ GWD_\")/_BJ.2(?7\1W7W+_(/^$4T?\
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M^?>3_P ")/\ XJCDB'U_$=U]R_R#_A%-'_Y]Y/\ P(D_^*HY(A]?Q'=?<O\
M(/\ A%-'_P"?>3_P(D_^*HY(A]?Q'=?<O\@_X131_P#GWD_\")/_ (JCDB'U
M_$=U]R_R#_A%-'_Y]Y/_  (D_P#BJ.2(?7\1W7W+_(/^$4T?_GWD_P# B3_X
MJCDB'U_$=U]R_P @_P"$4T?_ )]Y/_ B3_XJCDB'U_$=U]R_R#_A%-'_ .?>
M3_P(D_\ BJ.2(?7\1W7W+_(VJLX0H * "@ H 3 !SB@!: "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
/* "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
